Market capitalization | $1.54b |
Enterprise Value | $1.35b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.53 |
P/S ratio (TTM) P/S ratio | 5.19 |
P/B ratio (TTM) P/B ratio | 5.82 |
Revenue growth (TTM) Revenue growth | -3.95% |
Revenue (TTM) Revenue | $297.08m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
9 Analysts have issued a CareDx, Inc. forecast:
9 Analysts have issued a CareDx, Inc. forecast:
Dec '23 | |
Current assets | 314 314 |
Fixed assets | 171 171 |
Total Assets | 485 485 |
Dec '23 | |
Equity | 261 261 |
Debt capital | 223 223 |
Total Capital | 485 485 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
CareDx, Inc. operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
Head office | United States |
CEO | John Hanna |
Employees | 643 |
Founded | 1998 |
Website | www.caredx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.